دورية أكاديمية
Impact of alogliptin on lipopolysaccharide-induced experimental Parkinson's disease: Unrevealing neurochemical and histopathological alterations in rodents.
| العنوان: | Impact of alogliptin on lipopolysaccharide-induced experimental Parkinson's disease: Unrevealing neurochemical and histopathological alterations in rodents. |
|---|---|
| المؤلفون: | Dhureja M; Department of Pharmaceutical Sciences & Technology, MRSPTU, Bathinda, India., Deshmukh R; Department of Pharmaceutical Sciences & Technology, MRSPTU, Bathinda, India; Department of Pharmacology, Central University of Punjab, Ghudda, Bathinda, India. Electronic address: drrahuld09@gmail.com. |
| المصدر: | European journal of pharmacology [Eur J Pharmacol] 2024 Jul 15; Vol. 975, pp. 176635. Date of Electronic Publication: 2024 May 10. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2005- : Amsterdam : Elsevier Science Original Publication: Amsterdam, North Holland Pub. Co. |
| مواضيع طبية MeSH: | Lipopolysaccharides* , Uracil*/analogs & derivatives , Uracil*/pharmacology , Uracil*/therapeutic use , Piperidines*/pharmacology , Piperidines*/therapeutic use , Neuroprotective Agents*/pharmacology , Neuroprotective Agents*/therapeutic use , Dipeptidyl-Peptidase IV Inhibitors*/pharmacology , Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use , Oxidative Stress*/drug effects, Animals ; Male ; Rats ; Rats, Wistar ; Disease Models, Animal ; Parkinson Disease/drug therapy ; Parkinson Disease/metabolism ; Parkinson Disease/pathology ; Cytokines/metabolism ; Motor Activity/drug effects ; Corpus Striatum/drug effects ; Corpus Striatum/metabolism ; Corpus Striatum/pathology |
| مستخلص: | Background: Degeneration of the nigrostriatal dopaminergic pathway has been seen as a significant cause of movement disability in Parkinson's disease (PD) patients. However, the exact reason for these degenerative changes has remained obscure. In recent years, incretins have been neuroprotective in various pathologies. In the current study, we have investigated the neuroprotective potential of alogliptin (Alo), a dipeptidyl peptidase-IV (DPP-IV) inhibitor, in a lipopolysaccharide (LPS) induced experimental model of PD. Experimental Approach: LPS (5μg/5 μl) was infused intranigrally to induce PD in experimental rats. Post-LPS infusion, these animals were treated with Alo for 21 days in three successive dosages of 10, 20, and 40 mg/kg/day/per oral. The study is well supported with the determinations of motor functions biochemical, neurochemical, and histological analysis. Key Results: Intranigral infusion of LPS in rats produced motor deficit. It was accompanied by oxidative stress, elevation in neuroinflammatory cytokines, altered neurochemistry, and degenerative changes in the striatal brain region. While Alo abrogated LPS-induced biochemical/neurochemical alterations, improved motor functions, and preserved neuronal morphology in LPS-infused rats. Conclusion: The observed neuroprotective potential of Alo may be due to its antioxidant and anti-inflammatory actions and its ability to modulate monoaminergic signals. Nonetheless, current findings suggest that improving the availability of incretins through DPP-IV inhibition is a promising strategy for treating Parkinson's disease. Competing Interests: Declaration of competing interest Authors do not have any conflict of interest. (Copyright © 2024 Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Alogliptin; Dopamine; Neurochemistry; Neuroinflammation; Oxidative stress; Parkinson's disease |
| المشرفين على المادة: | 0 (Lipopolysaccharides) 56HH86ZVCT (Uracil) JHC049LO86 (alogliptin) 0 (Piperidines) 0 (Neuroprotective Agents) 0 (Dipeptidyl-Peptidase IV Inhibitors) 0 (Cytokines) |
| تواريخ الأحداث: | Date Created: 20240511 Date Completed: 20240603 Latest Revision: 20240603 |
| رمز التحديث: | 20240604 |
| DOI: | 10.1016/j.ejphar.2024.176635 |
| PMID: | 38734296 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1879-0712 |
|---|---|
| DOI: | 10.1016/j.ejphar.2024.176635 |